SERS-based DNA methylation profiling allows the differential diagnosis of malignant lymphadenopathy.


Journal

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
ISSN: 1873-3557
Titre abrégé: Spectrochim Acta A Mol Biomol Spectrosc
Pays: England
ID NLM: 9602533

Informations de publication

Date de publication:
05 Jan 2022
Historique:
received: 24 04 2021
revised: 12 07 2021
accepted: 17 07 2021
pubmed: 8 8 2021
medline: 27 10 2021
entrez: 7 8 2021
Statut: ppublish

Résumé

This study highlights the potential of surface-enhanced Raman scattering (SERS) to differentiate between B-cell lymphoma (BCL), T-cell lymphoma (TCL), lymph node metastasis of melanoma (Met) and control (Ctr) samples based on the specific SERS signal of DNA extracted from lymph node tissue biopsy. Differences in the methylation profiles as well as the specific interaction of malignant and non-malignant DNA with the metal nanostructure are captured in specific variations of the band at 1005 cm

Identifiants

pubmed: 34364036
pii: S1386-1425(21)00793-9
doi: 10.1016/j.saa.2021.120216
pii:
doi:

Substances chimiques

DNA 9007-49-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

120216

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Andrei Stefancu (A)

Faculty of Physics, Babeș-Bolyai University, Cluj-Napoca, Romania.

Vlad Moisoiu (V)

Faculty of Physics, Babeș-Bolyai University, Cluj-Napoca, Romania.

Minodora Desmirean (M)

Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; Department of Pathology, Constantin Papilian Military Hospital, Cluj-Napoca, Romania.

Stefania D Iancu (SD)

Faculty of Physics, Babeș-Bolyai University, Cluj-Napoca, Romania.

Adrian B Tigu (AB)

Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.

Bobe Petrushev (B)

Department of Pathology, Octavian Fodor Gastroenterology Institute, Cluj-Napoca, Romania.

Ancuta Jurj (A)

Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Ramona G Cozan (RG)

Faculty of Physics, Babeș-Bolyai University, Cluj-Napoca, Romania.

Liviuta Budisan (L)

Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Bogdan Fetica (B)

Department of Pathology, "Prof. Dr. Ion Chiricuță" Institute of Oncology, Cluj-Napoca, Romania.

Andrei Roman (A)

Department of Radiology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; Department of Radiology, "Prof. Dr. Ion Chiricuță" Institute of Oncology, Cluj-Napoca, Romania.

Gina Dobie (G)

Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Cristina Turcas (C)

Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Mihnea Zdrenghea (M)

Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; Department of Hematology, "Prof. Dr. Ion Chiricuță" Institute of Oncology, Cluj-Napoca, Romania.

Patric Teodorescu (P)

Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; Department of Hematology, "Prof. Dr. Ion Chiricuță" Institute of Oncology, Cluj-Napoca, Romania.

Sergiu Pasca (S)

Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; Department of Hematology, "Prof. Dr. Ion Chiricuță" Institute of Oncology, Cluj-Napoca, Romania.

Doina Piciu (D)

Department of Nuclear Medicine, "Prof. Dr. Ion Chiricuță" Institute of Oncology, Cluj-Napoca, Romania.

Delia Dima (D)

Department of Hematology, "Prof. Dr. Ion Chiricuță" Institute of Oncology, Cluj-Napoca, Romania.

Zoltán Bálint (Z)

Faculty of Physics, Babeș-Bolyai University, Cluj-Napoca, Romania.

Nicolae Leopold (N)

Faculty of Physics, Babeș-Bolyai University, Cluj-Napoca, Romania; Biomed Data Analytics SRL, Cluj-Napoca, Romania. Electronic address: nicolae.leopold@ubbcluj.ro.

Ciprian Tomuleasa (C)

Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania; Department of Hematology, "Prof. Dr. Ion Chiricuță" Institute of Oncology, Cluj-Napoca, Romania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH